Standard Treatment Regimens for Nongonococcal Urethritis Have Similar but Declining Cure Rates: A Randomized Controlled Trial

被引:155
作者
Manhart, Lisa E. [1 ,2 ]
Gillespie, Catherine W. [1 ,6 ]
Lowens, M. Sylvan [5 ]
Khosropour, Christine M. [1 ]
Colombara, Danny V. [1 ]
Golden, Matthew R. [3 ,5 ]
Hakhu, Navneet R. [4 ]
Thomas, Katherine K. [3 ]
Hughes, James P. [4 ]
Jensen, Nicole L. [3 ]
Totten, Patricia A. [3 ]
机构
[1] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA
[3] Univ Washington, Dept Med, Seattle, WA 98104 USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98104 USA
[5] STD Program, Seattle, WA USA
[6] Childrens Natl Med Ctr, Washington, DC 20010 USA
基金
美国国家卫生研究院;
关键词
urethritis; treatment; Mycoplasma genitalium; Chlamydia trachomatis; randomized trial; MYCOPLASMA-GENITALIUM; DOUBLE-BLIND; AZITHROMYCIN; MEN; INFECTION; THERAPY; AMPLIFICATION; MOXIFLOXACIN; ERADICATION; PERSISTENCE;
D O I
10.1093/cid/cis1022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Azithromycin or doxycycline is recommended for nongonococcal urethritis (NGU); recent evidence suggests their efficacy has declined. We compared azithromycin and doxycycline in men with NGU, hypothesizing that azithromycin was more effective than doxycycline. Methods. From January 2007 to July 2011, English-speaking males >= 16 years, attending a sexually transmitted diseases clinic in Seattle, Washington, with NGU (visible urethral discharge or >= 5 polymorphonuclear leukocytes per high-power field [PMNs/HPF]) were eligible for this double-blind, parallel-group superiority trial. Participants received active azithromycin (1 g) + placebo doxycycline or active doxycycline (100 mg twice daily for 7 days) + placebo azithromycin. Urine was tested for Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), Urea plasma urealyticum biovar 2 (UU-2), and Trichomonas vaginalis (TV) using nucleic acid amplification tests. Clinical cure (<5 PMNs/HPF with or without urethral symptoms and absence of discharge) and microbiologic cure (negative tests for CT, MG, and/or UU-2) were determined after 3 weeks. Results. Of 606 men, 304 were randomized to azithromycin and 302 to doxycycline; CT, MG, TV, and UU-2 were detected in 24%, 13%, 2%, and 23%, respectively. In modified intent-to-treat analyses, 172 of 216 (80%; 95% confidence interval [CI], 74%-85%) receiving azithromycin and 157 of 206 (76%; 95% CI, 70%-82%) receiving doxycycline experienced clinical cure (P = .40). In pathogen-specific analyses, clinical cure did not differ by arm, nor did microbiologic cure differ for CT (86% vs 90%, P = .56), MG (40% vs 30%, P = .41), or UU-2 (75% vs 70%, P = .50). No unexpected adverse events occurred. Conclusions. Clinical and microbiologic cure rates for NGU were somewhat low and there was no significant difference between azithromycin and doxycycline. Mycoplasma genitalium treatment failure was extremely common. Clinical Trials Registration. NCT00358462.
引用
收藏
页码:934 / 942
页数:9
相关论文
共 50 条
  • [41] Cellular Proliferation, Dermal Repair, and Microbiological Effectiveness of Ultrasound-Assisted Wound Debridement (UAW) Versus Standard Wound Treatment in Complicated Diabetic Foot Ulcers (DFU): An Open-Label Randomized Controlled Trial
    Luis Lazaro-Martinez, Jose
    Javier Alvaro-Afonso, Francisco
    Sevillano-Fernandez, David
    Garcia-Alvarez, Yolanda
    Sanz-Corbalan, Irene
    Garcia-Morales, Esther
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (12) : 1 - 13
  • [42] Mediators of Ethnic Differences in Dropout Rates From a Randomized Controlled Treatment Trial Among Latinx and Non-Latinx White Primary Care Patients With Anxiety Disorders
    Escovar, Emily L.
    Bocanegra, Elizabeth S.
    Craske, Michelle G.
    Bystritsky, Alexander
    Roy-Byrne, Peter
    Sherbourne, Cathy D.
    Stein, Murray B.
    Chavira, Denise A.
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2023, 211 (06) : 427 - 439
  • [43] A feasibility study of standard dressings versus negative-pressure wound therapy in the treatment of adult patients having surgical incisions for hip fractures: the WHISH randomized controlled trial
    Masters, J.
    Cook, J.
    Achten, J.
    Costa, M. L.
    BONE & JOINT JOURNAL, 2021, 103B (04) : 755 - 761
  • [44] Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand
    Garg, Shikha
    Thongcharoen, Prasert
    Praphasiri, Prabda
    Chitwarakorn, Anupong
    Sathirapanya, Pornchai
    Fernandez, Stefan
    Rungrojcharoenkit, Kamonthip
    Chonwattana, Wannee
    Mock, Philip A.
    Sukwicha, Wichuda
    Katz, Jacqueline M.
    Widdowson, Marc-Alain
    Curlin, Marcel E.
    Gibbons, Robert V.
    Holtz, Timothy H.
    Dawood, Fatimah S.
    Olsen, Sonja J.
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (03) : 383 - 391
  • [45] Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China
    Hu, Jie
    Mei, Hao
    Su, Na-yun
    Sun, Wen-jing
    Zhang, De-kui
    Fan, Li-lin
    He, Ping
    Pan, Jie
    Wang, Xing-wei
    Zou, Pei-ying
    Liu, Yu-xiang
    Guo, Yan
    Lan, Chun-Hui
    HELICOBACTER, 2023, 28 (04)
  • [46] Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial
    Akram, Javed
    Azhar, Shehnoor
    Shahzad, Muhammad
    Latif, Waqas
    Khan, Khalid Saeed
    TRIALS, 2020, 21 (01)
  • [47] Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial
    Javed Akram
    Shehnoor Azhar
    Muhammad Shahzad
    Waqas Latif
    Khalid Saeed Khan
    Trials, 21
  • [48] Comparison of the impact of autologous cell therapy and conservative standard treatment on tissue oxygen supply and course of the diabetic foot in patients with chronic limb-threatening ischemia: A randomized controlled trial
    Dubsky, Michal
    Husakova, Jitka
    Bem, Robert
    Jirkovska, Alexandra
    Nemcova, Andrea
    Fejfarova, Vladimira
    Sutoris, Karol
    Kahle, Michal
    Jude, Edward B.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [49] Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial
    Yao, Amanda H.
    Moore, Cecilia L.
    Lim, Poh Lian
    Molina, Jean-Michel
    Madero, Juan Sierra
    Kerr, Stephen
    Mallon, Paddy W. G.
    Emery, Sean
    Cooper, David A.
    Boyd, Mark A.
    Boyd, M. A.
    Kumarasamy, N.
    Moore, C. L.
    Nwizu, C.
    Losso, M. H.
    Mohapi, L.
    Martin, A.
    Kerr, S.
    Sohn, A. H.
    Teppler, H.
    Van de Steen, O.
    Molina, J-M
    Emery, S.
    Cooper, D. A.
    Belloso, W.
    Elliott, J.
    Emery, S.
    Gazzard, B.
    Gotuzzo, E.
    Humphries, A.
    Kamarulzaman, A.
    Kedem, E.
    ANTIVIRAL THERAPY, 2018, 23 (01) : 21 - 32
  • [50] The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial
    Watson, Marion
    Tillett, William
    Jadon, Deepak
    Massa, M. Sofia
    Francis, Anne
    Gullick, Nicola
    Rombach, Ines
    Sinomati, Yvonne
    Tucker, Laura
    Coates, Laura C.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2024, 16